KR910000731A - 4-아미노 3-카르복시 퀴놀린 및 나프티리딘, 그 제조방법 및 그의 의약품으로서 용도 - Google Patents

4-아미노 3-카르복시 퀴놀린 및 나프티리딘, 그 제조방법 및 그의 의약품으로서 용도 Download PDF

Info

Publication number
KR910000731A
KR910000731A KR1019890007791A KR890007791A KR910000731A KR 910000731 A KR910000731 A KR 910000731A KR 1019890007791 A KR1019890007791 A KR 1019890007791A KR 890007791 A KR890007791 A KR 890007791A KR 910000731 A KR910000731 A KR 910000731A
Authority
KR
South Korea
Prior art keywords
alkyl
compound
hydrogen
formula
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1019890007791A
Other languages
English (en)
Inventor
멍데 에띠앙
베르니에르 쟝-끌로드
위젠스 끼안 뻬떼르
바씨 앙드레
Original Assignee
미쉘 드 아스
사노피 쏘시에떼 아노님
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR8807498A external-priority patent/FR2632305B1/fr
Priority claimed from FR8808025A external-priority patent/FR2632861B1/fr
Application filed by 미쉘 드 아스, 사노피 쏘시에떼 아노님 filed Critical 미쉘 드 아스
Publication of KR910000731A publication Critical patent/KR910000731A/ko
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/58—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems with hetero atoms directly attached to the ring nitrogen atom
    • C07D215/60—N-oxides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Anesthesiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

내용 없음

Description

4-아미노3-카르복시 퀴놀린 및 나프티리딘, 그 제조방법 및 그의 의약품으로서 용도
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (22)

  1. 라세미체 또는 거울상 이성질체 형태의 식(Ⅰ)의 화합물 및 그의 약학적으로 허용될 수 있는 산 또는 염기부가염.
    위 식에서, R1과 R2는 같거나 다르며 각기 수소, C1-C6의 알킬, C2-C6의 알킬렌, 페닐, 벤질중의 하나이거나, R1과 R2는 그들이 결합된 질소와 함께 C4-C8의 포화헤테로사이클을 형성하고, R3는 수소, C1-C6의 알킬, 페닐 또는 C7-C9의 페닐알킬중의 하나이고, R4는 수소 또는 C1-C4의 알킬중의 하나이고 R5와 R6는 같거나 다르며 각기 수소, 할로겐, C1-C3의 알킬 또는 알콕시, 니트로 또는 트리플루오로메틸 중의 하나이거나 같이 메틸렌디옥시그룹을 형성하고, Z는 R7이 수소 또는 C1-C6의 알킬중의 하나인 OR7이거나; R8과 R9가 각기 수소, C1-C4의 알킬, 페닐, 벤질중의 하나인 NR8R9이거나; C1-C4의 알킬이거나; 벤질이거나; 헤테로원자가 있거나 또는 없는 C4-C6의 아릴이고, R10은 Z가 벤질 또는 페닐이 아니고 R3가 수소가 아니고, 페닐 및 벤질 그룹이 할로겐, C1-C3의 알콕시, 알킬 또는 티오알킬, 니트로, 트리플루오로 메틸 또는 하이드록시로 치환될 수 있고, 알킬 및 알콕시 그룹이 직쇄, 분지 또는 고리모양이라는 조건하에 수소, C1-C4의 알킬 또는 페닐 중의 하나이다. n은 0,1 또는 2이고, p는 0또는 1이며, A, B, C, D의 하나는 N이고 나머지 CH이거나, A, B, C, D 모두는 각기 CH를 나타낸다.
  2. 제1항에 있어서, Z가 치환 또는 미치환된 페닐그룹인 것을 특징으로 하는 식Ⅰ의 화합물.
  3. 제2항에 있어서, Z가 미치환된 페닐그룹인 것을 특징으로 하는 화합물.
  4. 제1항에 있어서, Z가 피리딜, 피롤릴, 푸릴, 티에닐 또는 이미다졸릴인 것을 특징으로 하는 식Ⅰ의 화합물.
  5. 제1항에 있어서, Z가 OR7인 것을 특징으로 하는 식Ⅰ의 화합물.
  6. 제5항에 있어서, R7이 알킬인 것을 특징으로 하는 화합물.
  7. 제5항에 있어서, Z가 C1-C3의 알킬인 것을 특징으로 하는 화합물.
  8. 제1항 내지 제7항 중 어느 한 항에 있어서, A, B, C, D가 각기 CH인 것을 특징으로 하는 식Ⅰ의 화합물.
  9. 제1항 내지 제7항 중 어느 한항에 있어서, A, B, C 또는 D중 어느 하나가 N인 것을 특징으로 하는 식Ⅰ의 화합물.
  10. 제9항에 있어서, A가 N인 것을 특징으로 하는 화합물.
  11. 제1항에 있어서, R1과 R2가 각기 의 C1-C6알킬이고, R3이 C1-C3의 알킬이고, R10이 수소이고, Z가 R7이 C1-C6의 알킬인 OR7인 것을 특징으로 하는 식Ⅰ의 화합물.
  12. 제11항에 있어서, R4가 수소인 것을 특징으로 하는 화합물.
  13. 제11항에 있어서, R4가 수소이고, C가 치환된 것을 특징으로 하는 화합물.
  14. 제1항에 있어서, R1가 알킬이고, R2및 Z가 각기 치환될 수 있는 페닐인 것을 특징으로 하는 식Ⅰ의 화합물.
  15. 제1항에 있어서, R1가 알킬이고, R2및 Z가 치환될 수 있는 페닐이고, R3과 R10이 각기 수소인 것을 특징으로 하는 식Ⅰ의 화합물.
  16. 제14항과 제15항중 어느 한항에 있어서, A, B, C, D가 각기 CH인 것을 특징으로 하는 화합물.
  17. 제14항과 제15항중 어느 한항에 있어서, A가 N이고 B, C 및 D가 CH인 것을 특징으로 하는 화합물.
  18. 에틸7-클로로4-(1-N,N-디프로필카르바모일)에틸 아미노 퀴놀린3-카르복시레이트 및 그의 약학적으로 허용할 수 있는 산부가염.
  19. 3-벤조일7-클로로4-(N-메틸N-4-클로로페닐)카르바모일 메틸아미노 퀴놀린 및 그의 약학적으로 허용될 수 있는 산부가염.
  20. 3-벤조일4-(N-메틸N-4-클로로페닐)카르바모일 메틸아미노 1,5-나프티리딘 및 그의 약학적으로 허용될 수 있는 산부가염.
  21. 식Ⅱ의 아민과 식Ⅲ의 화합물을 반응시키는 것을 특징으로 하는 식Ⅰ의 화합물을 제조하는 방법.
    위 식에서 R1, R2, R3, R4, R5, R6, R10, Z, A, B, C, D, n 및 p는 제1항과 같은 의미이고 X는 할로겐 또는 설포네이트 중의 하나이다.
  22. 양립할 수 있는 부형제 뿐만 아니라 제1항 내지 제20항중 어는 한 항에 의한 화합물을 유효성분으로 함유하는 약학적인 조성물.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019890007791A 1988-06-06 1989-06-05 4-아미노 3-카르복시 퀴놀린 및 나프티리딘, 그 제조방법 및 그의 의약품으로서 용도 Withdrawn KR910000731A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
FR8807498A FR2632305B1 (fr) 1988-06-06 1988-06-06 Amino-4 aroyl-3 quinoleines et naphtyridines, leur procede de preparation et leur application en therapeutique
FR88-07498 1988-06-06
FR88-08025 1988-06-15
FR8808025A FR2632861B1 (fr) 1988-06-15 1988-06-15 Derives d'amino-4 carboxy-3 quinoleines et naphtyridines, leur procede de preparation et leur application comme medicaments

Publications (1)

Publication Number Publication Date
KR910000731A true KR910000731A (ko) 1991-01-30

Family

ID=26226703

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019890007791A Withdrawn KR910000731A (ko) 1988-06-06 1989-06-05 4-아미노 3-카르복시 퀴놀린 및 나프티리딘, 그 제조방법 및 그의 의약품으로서 용도

Country Status (12)

Country Link
US (1) US5026711A (ko)
EP (1) EP0346208B1 (ko)
JP (1) JP2766672B2 (ko)
KR (1) KR910000731A (ko)
AU (1) AU624825B2 (ko)
CA (1) CA1337073C (ko)
DE (1) DE68914515T2 (ko)
DK (1) DK273689A (ko)
ES (1) ES2063153T3 (ko)
IE (1) IE63429B1 (ko)
NZ (1) NZ229413A (ko)
PT (1) PT90748B (ko)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5215999A (en) * 1990-03-28 1993-06-01 Otsuka Pharmaceutical Co., Ltd. Quinoline derivative and antiulcer agent containing said quinoline derivative
US5395399A (en) * 1993-06-14 1995-03-07 Sport Wrapz, Inc. Thermal wrap for a body member
DE4405712A1 (de) * 1994-02-23 1995-08-24 Basf Ag Substituierte Naphthyridine und deren Verwendung
IL117659A (en) * 1995-04-13 2000-12-06 Dainippon Pharmaceutical Co Substituted 2-phenyl pyrimidino amino acetamide derivative process for preparing the same and a pharmaceutical composition containing same
KR0169813B1 (ko) * 1995-07-12 1999-01-15 김종인 4-아미노-3-아실나프티리딘 유도체
AU7474998A (en) * 1997-05-07 1998-11-27 Emory University Haloisoquinoline carboxamide
ZA9810490B (en) 1997-12-03 1999-05-20 Dainippon Pharmaceutical Co 2-Aryl-8-oxodihydropurine derivative process for the preparation thereof pharmaceutical composition containing the same and intermediate therefor
FR2778564B1 (fr) * 1998-05-13 2001-07-13 Sanofi Sa Utilisation de composes reduisant l'apoptose
WO1999058117A1 (fr) * 1998-05-13 1999-11-18 Sanofi-Synthelabo Utilisation de composes reduisant l'apoptose
AU2185100A (en) 1998-12-18 2000-07-12 Scios Inc. Agonists and antagonists of peripheral-type benzodiazepine receptors
EP1140106B1 (en) * 1998-12-18 2005-08-03 Scios Inc. Treatment of diseases involving cyst formation
DE19960924C2 (de) * 1999-12-17 2002-08-01 Therapeutics Gmbh G.O.T. Amphiphile Polyamine, deren Anwendungen
FR2862301B1 (fr) * 2003-11-17 2007-12-21 Aventis Pharma Sa Nouveau procede de preparation de quinoleines 3-fluorees
SE0400284D0 (sv) * 2004-02-10 2004-02-10 Astrazeneca Ab Novel compounds
US8354427B2 (en) 2004-06-24 2013-01-15 Vertex Pharmaceutical Incorporated Modulators of ATP-binding cassette transporters
CN101891680B (zh) 2004-06-24 2014-10-29 沃泰克斯药物股份有限公司 Atp-结合弹夹转运蛋白的调控剂
CN101374849A (zh) * 2005-12-24 2009-02-25 沃泰克斯药物股份有限公司 作为abc转运蛋白调控剂的喹啉-4-酮衍生物
DK3219705T3 (da) 2005-12-28 2020-04-14 Vertex Pharma Farmaceutiske sammensætninger af den amorfe form af n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinolin-3-carboxamid
TW200829555A (en) * 2006-11-10 2008-07-16 Astrazeneca Ab Chemical compounds
CL2008000191A1 (es) * 2007-01-25 2008-08-22 Astrazeneca Ab Compuestos derivados de 4-amino-cinnotina-3-carboxamida; inhibidores de csf-1r quinasa; su proceso de preparacion; y su uso para tratar el cancer.
JP2011520804A (ja) * 2008-05-07 2011-07-21 アストラゼネカ アクチボラグ 化合物
US20100074949A1 (en) 2008-08-13 2010-03-25 William Rowe Pharmaceutical composition and administration thereof
US12458635B2 (en) 2008-08-13 2025-11-04 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administrations thereof
EP2401275B1 (en) 2009-02-24 2013-07-24 Respiratorius AB Naphthyridine derivatives having bronchodilating activity
KR101727762B1 (ko) 2009-03-20 2017-04-17 버텍스 파마슈티칼스 인코포레이티드 낭성 섬유증 막횡단 전도도 조절자의 조정자의 제조 방법
US8802700B2 (en) 2010-12-10 2014-08-12 Vertex Pharmaceuticals Incorporated Modulators of ATP-Binding Cassette transporters
CN104968345B (zh) * 2012-01-19 2018-05-08 肿瘤疗法科学股份有限公司 1,5-萘啶衍生物和含1,5-萘啶衍生物的melk抑制剂
JP2015511583A (ja) 2012-02-27 2015-04-20 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ 薬学的組成物およびその投与
CN107250113B (zh) 2014-10-07 2019-03-29 弗特克斯药品有限公司 囊性纤维化跨膜传导调节蛋白的调节剂的共晶
WO2026055338A1 (en) * 2024-09-06 2026-03-12 Genentech, Inc. Tmem175 modulators

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4324893A (en) * 1979-04-18 1982-04-13 American Home Products Corporation 4-Amino-3-carboxy or cyano-1,2-dihydro-2-oxo-1,8-naphthyridine derivatives
FR2581382B1 (fr) * 1985-05-06 1987-06-26 Sanofi Sa Derives n-(quinolyl) glycinamides, leur procede de preparation et leur application therapeutique en tant que psychotropes
GB8610981D0 (en) * 1986-05-06 1986-06-11 Ici America Inc Quinoline amides
GB8621425D0 (en) * 1986-09-05 1986-10-15 Smith Kline French Lab Compounds
AU634561B2 (en) * 1989-07-27 1993-02-25 Eli Lilly And Company Naphthyridine derivatives
US5034393A (en) * 1989-07-27 1991-07-23 Dowelanco Fungicidal use of pyridopyrimidine, pteridine, pyrimidopyrimidine, pyrimidopyridazine, and pyrimido-1,2,4-triazine derivatives

Also Published As

Publication number Publication date
NZ229413A (en) 1990-11-27
ES2063153T3 (es) 1995-01-01
DK273689A (da) 1989-12-07
IE891797L (en) 1989-12-06
IE63429B1 (en) 1995-04-19
PT90748B (pt) 1994-10-31
AU3603589A (en) 1989-12-07
JPH0232058A (ja) 1990-02-01
AU624825B2 (en) 1992-06-25
JP2766672B2 (ja) 1998-06-18
DK273689D0 (da) 1989-06-02
US5026711A (en) 1991-06-25
EP0346208B1 (fr) 1994-04-13
DE68914515D1 (de) 1994-05-19
DE68914515T2 (de) 1994-08-18
PT90748A (pt) 1989-12-29
EP0346208A1 (fr) 1989-12-13
CA1337073C (en) 1995-09-19

Similar Documents

Publication Publication Date Title
MX9306831A (es) Nuevos compuestos heterociclicos.
PT96324A (pt) Processo para a preparacao de compostos peptidicos e de composicoes farmaceuticas que os contem
IE37538B1 (en) New 1,4-dihydropyridine carboxylic acid compounds their production and their medicinal use
KR890000485A (ko) 캠프토데신 유도체 및 그의 아미노기에 있어서의 산 부가염 및 4급 암모늄염 및 그의 제조방법
ATE126216T1 (de) Pyrazolderivate, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammenstellung.
NO990227D0 (no) Heterocykliske forbindelser som farmas°ytika
DE3873612D1 (de) Dithioacetal-verbindungen, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammensetzungen.
KR900016220A (ko) 매크로리드 조성물
ES2029384T4 (es) Procedimiento para preparar nuevas 3,3-difenilpropilaminas.
SU1279528A1 (ru) "cпocoб пoлучehия 1,4-дигидpoпиpидиhob или иx гидpoxлopидob"
DK0516941T3 (da) Pyrazolopyridinforbindelser og fremgangsmåder til fremstilling deraf
KR920021547A (ko) 아졸 유도체
KR890014522A (ko) 사이클릭 이미드의 아릴피페라지닐알콕시 유도체, 이의 제조방법 및 약제로서의 이의 용도
KR890001957A (ko) N-아미노부틸-n-페닐아릴아미드 유도체, 그의 제법 및 치료에의 응용
KR880001681A (ko) 신규 1h, 3h-피롤로[1,2-c]티아졸 유도체, 그의 제조 방법 및 그들을 함유한 제약조성물
KR910009672A (ko) 피리다진 유도체, 이의 제조방법 및 이것을 함유하는 약학 조성물
KR900014396A (ko) 티에노-트리아졸로-디아제핀 유도체, 그의 제조 방법 및 그를 함유하는 치료 조성물
OA09119A (fr) Nouveaux céphèmes et leur préparation.
HUT40080A (en) Process for preparing 1,4-dihydro-pyridine-hydroxy-amine derivatives and pharmaceutical compositions comprising the same as active substance
DK160486C (da) N-(4-amino-2,2-diphenyl-butyl)- eller n-(3-amino-2,2-diphenyl-propyl) urinstofforbindelser, fremgangsmaade til fremstilling af disse, samt en farmaceutisk komposition
DE3668888D1 (de) Ein imidazolidintrion-derivat oder ein seiner pharmazeutisch akzeptierbaren salze enthaltende pharmazeutische zusammenstellung.
AR013004A1 (es) Derivados de aminospiropiperidina quinazolina, composicion farmaceutica, uso de dichos derivados en la preparacion de medicamentos, proceso para lapreparacion de dichos derivados y compuestos intermediarios para su exclusivo uso en dicho proceso.
DK417380A (da) Analogifremgangsmaade til fremstilling af nitrosourinstofderivater eller syreadditionssalte deraf
PT85547A (pt) Processo de preparacao de composicao farmaceuticas a base de derivados de 2-mercapto-imidazol e de preparacao destes derivados
BR0202313A (pt) Compostos cìclicos de alfa-amino-gama-hidroxiamida, um processo para a preparação dos mesmos e composições farmacêuticas que contem os mesmos

Legal Events

Date Code Title Description
PA0109 Patent application

Patent event code: PA01091R01D

Comment text: Patent Application

Patent event date: 19890605

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid